A prospective, non-randomized phase II trial of Trastuzumab and Capecitabine in patients with HER2 expressing metastasized pancreatic cancer

BMC Surgery

Volumn 9, Issue 1, 2009, Pages

  Büchler, Peter ^a   Mihaljevic, Andre ^a,l   Harder, Jan ^b   Hofheinz, Ralf ^e   Gregor, Michael ^c   Kanzler, Stephan ^d   Schmiegel, Wolff ^f   Heinemann, Volker ^g   Endlicher, Esther ^h   Klöppel, Günter ⁱ   Seufferlein, Thomas ^j   Geissler, Michael ^k  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b UNIVERSITY OF FREIBURG   (Germany)

^c UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^d JOHANNES GUTENBERG UNIVERSITY   (Germany)

^e UNIVERSITY OF HEIDELBERG   (Germany)

^f RUHR UNIVERSITY BOCHUM   (Germany)

^g LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^h UNIVERSITY OF REGENSBURG   (Germany)

ⁱ UNIVERSITY OF KIEL   (Germany)

^j UNIVERSITY OF ULM   (Germany)

^k Municipal Hospital Esslingen   (Germany)

^l TECHNICAL UNIVERSITY OF MUNICH   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; PROTEIN TYROSINE KINASE; TRASTUZUMAB; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE; DRUG DERIVATIVE; FLUOROURACIL; MONOCLONAL ANTIBODY;

ARTICLE; CANCER STAGING; CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE EXPRESSION; HUMAN; IMMUNOHISTOCHEMISTRY; METASTASIS; PANCREAS CANCER; PROTEIN EXPRESSION; ADULT; BIOSYNTHESIS; METABOLISM; METHODOLOGY; MULTICENTER STUDY; PANCREAS TUMOR; PHASE 2 CLINICAL TRIAL; PROSPECTIVE STUDY;

ADULT; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS, PHASE II AS TOPIC; DEOXYCYTIDINE; FLUOROURACIL; HUMANS; MULTICENTER STUDIES AS TOPIC; PANCREATIC NEOPLASMS; PROSPECTIVE STUDIES; RECEPTOR, ERBB-2; RESEARCH DESIGN;

EID: 63349089247     PISSN: None     EISSN: 14712482     Source Type: Journal    
DOI: 10.1186/1471-2482-9-1     Document Type: Article

References (25)

1. Cancer statistics, 2008. A Jemal R Siegel E Ward Y Hao J Xu T Murray MJ Thun, CA Cancer J Clin 2008 58 71 96 10.3322/CA.2007.0010 18287387
2. Differences in survival by histologic type of pancreatic cancer. MD Fesinmeyer MA Austin CI Li AJ De Roos DJ Bowen, Cancer Epidemiol Biomarkers Prev 2005 14 1766 1773 10.1158/1055-9965.EPI-05-0120 16030115
3. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. HA Burris III MJ Moore J Andersen MR Green ML Rothenberg MR Modiano MC Cripps RK Portenoy AM Storniolo P Tarassoff R Nelson FA Dorr CD Stephens DD Von Hoff, J Clin Oncol 1997 15 2403 2413 9196156
4. Meta-analyses of chemotherapy for locally advanced and metastatic pancreatic cancer. A Sultana CT Smith D Cunningham N Starling JP Neoptolemos P Ghaneh, J Clin Oncol 2007 25 2607 2615 10.1200/JCO.2006.09.2551 17577041
5. Clinical pharmacokinetics of capecitabine. B Reigner K Blesch E Weidekamm, Clin Pharmacokinet 2001 40 85 104 10.2165/00003088-200140020-00002 11286326
6. Phase II study of oral capecitabine in patients with advanced or metastatic pancreatic cancer. TH Cartwright A Cohn JA Varkey YM Chen TP Szatrowski JV Cox JJ Schulz, J Clin Oncol 2002 20 160 164 10.1200/JCO.20.1.160 11773165
7. Combining capecitabine and gemcitabine in patients with advanced pancreatic carcinoma: a phase I/II trial. V Hess M Salzberg M Borner R Morant AD Roth C Ludwig R Herrmann, J Clin Oncol 2003 21 66 68 10.1200/JCO.2003.04.029 12506172
8. Risk factors and prevention of cardiotoxicity induced by 5-fluorouracil or capecitabine. SA Jensen JB Sorensen, Cancer Chemother Pharmacol 2006 58 487 493 10.1007/s00280-005-0178-1 16418875
9. Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group. R Herrmann G Bodoky T Ruhstaller B Glimelius E Bajetta J Schuller P Saletti J Bauer A Figer B Pestalozzi CH Kohne W Mingrone SM Stemmer K Tamas GV Kornek D Koeberle S Cina J Bernhard D Dietrich W Scheithauer, J Clin Oncol 2007 25 2212 2217 10.1200/JCO.2006.09.0886 17538165
10. Clinical benefit and quality of life in patients with advanced pancreatic cancer receiving gemcitabine plus capecitabine versus gemcitabine alone: a randomized multicenter phase III clinical trial - SAKK 44/00-CECOG/PAN.1.3.001. J Bernhard D Dietrich W Scheithauer D Gerber G Bodoky T Ruhstaller B Glimelius E Bajetta J Schuller P Saletti J Bauer A Figer BC Pestalozzi CH Kohne W Mingrone SM Stemmer K Tamas GV Kornek D Koeberle R Herrmann, J Clin Oncol 2008 26 3695 3701 10.1200/JCO.2007.15.6240 18669454
11. Capecitabine plus oxaliplatin (CapOx) versus capecitabine plus gemcitabine (CapGem) versus gemcitabine plus oxaliplatin (mGemOx): final results of a multicenter randomized phase II trial in advanced pancreatic cancer. S Boeck T Hoehler G Seipelt R Mahlberg A Wein A Hochhaus HP Boeck B Schmid E Kettner M Stauch F Lordick Y Ko M Geissler K Schoppmeyer G Kojouharoff A Golf S Neugebauer V Heinemann, Ann Oncol 2008 19 340 347 10.1093/annonc/mdm467 17962204
12. Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer. MD Pegram GE Konecny C O'Callaghan M Beryt R Pietras DJ Slamon, J Natl Cancer Inst 2004 96 739 749 15150302
13. Therapy for pancreatic cancer with a recombinant humanized anti-HER2 antibody (herceptin). P Buchler HA Reber MC Buchler MA Roth MW Buchler H Friess WH Isacoff OJ Hines, J Gastrointest Surg 2001 5 139 146 10.1016/S1091-255X(01) 80025-1 11331475
14. Antitumor effect of trastuzumab for pancreatic cancer with high HER-2 expression and enhancement of effect by combined therapy with gemcitabine. K Kimura T Sawada M Komatsu M Inoue K Muguruma T Nishihara Y Yamashita N Yamada M Ohira K Hirakawa, Clin Cancer Res 2006 12 4925 4932 10.1158/1078-0432.CCR-06- 0544 16914581
15. Combination therapy for advanced pancreatic cancer using Herceptin plus chemotherapy. P Buchler HA Reber G Eibl MA Roth MW Buchler H Friess WH Isacoff OJ Hines, Int J Oncol 2005 27 1125 1130 16142331
16. Overexpression of the HER-2/neu oncogene in pancreatic adenocarcinoma. H Safran M Steinhoff S Mangray R Rathore TC King L Chai K Berzein T Moore D Iannitti P Reiss T Pasquariello P Akerman D Quirk R Mass L Goldstein U Tantravahi, Am J Clin Oncol 2001 24 496 499 10.1097/00000421-200110000-00016 11586103
17. Herceptin and gemcitabine for metastatic pancreatic cancers that overexpress HER-2/neu. H Safran D Iannitti R Ramanathan JD Schwartz M Steinhoff C Nauman P Hesketh R Rathore R Wolff U Tantravahi TM Hughes C Maia T Pasquariello L Goldstein T King JY Tsai T Kennedy, Cancer Invest 2004 22 706 712 10.1081/CNV-200032974 15581051
18. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. NK Aaronson S Ahmedzai B Bergman M Bullinger A Cull NJ Duez A Filiberti H Flechtner SB Fleishman JC de Haes, J Natl Cancer Inst 1993 85 365 376 10.1093/jnci/85.5.365 8433390
19. Test/retest study of the European Organization for Research and Treatment of Cancer Core Quality-of-Life Questionnaire. MJ Hjermstad SD Fossa K Bjordal S Kaasa, J Clin Oncol 1995 13 1249 1254 7738629
20. Optimal two-stage designs for phase II clinical trials. R Simon, Control Clin Trials 1989 10 1 10 10.1016/0197-2456(89)90015-9 2702835
21. Gemcitabine in the treatment of advanced pancreatic cancer: a comparative analysis of randomized trials. V Heinemann, Semin Oncol 2002 29 9 16 12577228
22. Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial. WF Regine KA Winter RA Abrams H Safran JP Hoffman A Konski AB Benson JS Macdonald MR Kudrimoti ML Fromm MG Haddock P Schaefer CG Willett TA Rich, JAMA 2008 299 1019 1026 10.1001/jama.299.9.1019 18319412
23. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. JP Neoptolemos DD Stocken H Friess C Bassi JA Dunn H Hickey H Beger L Fernandez-Cruz C Dervenis F Lacaine M Falconi P Pederzoli A Pap D Spooner DJ Kerr MW Buchler, N Engl J Med 2004 350 1200 1210 10.1056/NEJMoa032295 15028824
24. PKC 412 small-molecule tyrosine kinase inhibitor: single-compound therapy for pancreatic cancer. J El Fitori Y Su P Buchler R Ludwig NA Giese MW Buchler H Quentmeier OJ Hines I Herr H Friess, Cancer 2007 110 1457 1468 10.1002/cncr.22931 17676584
25. Target therapy using a small molecule inhibitor against angiogenic receptors in pancreatic cancer. P Buchler HA Reber MM Roth M Shiroishi H Friess OJ Hines, Neoplasia 2007 9 119 127 17356708 10.1593/neo.06616